Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15095 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Seung Min Chung und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Piperidones, Pyrimidines, Hypoglycemic Agents. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Daewoong Pharmaceutical Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To investigate the effects of gemigliptin on cardiac function and compare the effects of gemigliptin and glimepiride in patients with type 2 diabetes (T2D). Materials and Methods Sixty T2D patients being treated with metformin were assigned to a gemigliptin group (50 mg daily) or a glimepiride group (2 mg daily) for 24 weeks. The preadjudicated extension period was up to 52 weeks. Glucose metabolism variables and cardiac biomarkers were measured. Echocardiography was used to evaluate cardiac functions.
Results
The HbA1c levels decreased significantly from 8.1% ± 0.6% to 6.8% ± 0.6% in the gemigliptin group and from 8.1% ± 0.6% to 7.0% ± 0.7% in the glimepiride group, without a between‐group difference. Gemigliptin reduced insulin resistance, high sensitivity C‐reactive protein and low‐density lipoprotein cholesterol levels, and blood pressure, and increased adiponectin level compared with glimepiride therapy. Gemigliptin induced favourable changes in body composition. Left ventricular end‐diastolic volume decreased in the gemigliptin group but increased in the glimepiride group, with a borderline between‐group difference. Cardiac biomarkers did not change significantly in either group. At 52 weeks, the HbA1c levels in both groups increased slightly; 7.3% ± 0.8% in the gemigliptin group versus 7.7% ± 1.3% in the glimepiride group, without a between‐group difference.
Conclusions
Gemigliptin had a comparable glucose‐lowering efficacy without deleterious effects on cardiac functions or on biomarkers reflective of myocardial injury or heart failure during the 24‐week observation period. However, larger, longer‐term studies are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji University Hospital, School of Medicine, Daejeon, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
ORCID-Profile: Seung Min Chung, Jun Sung Moon, Soo Lim
Förderung
- Daewoong Pharmaceutical Company
Zitieren
APA
Chung, S. M., Moon, J. S., Hong, J. H., Hwang, I. C., & Lim, S. (2023). Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15095
Vancouver
Chung SM, Moon JS, Hong JH, Hwang IC, Lim S. Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15095
BibTeX
@article{Chung2023,
author = {Chung, Seung Min and Moon, Jun Sung and Hong, Jun Hwa and Hwang, In-Chang and Lim, Soo},
title = {Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15095}
}
EUVIMED